Andras Perl, MD
Rheumatology · Syracuse, NYNPI 1558393546
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $6,600 of the $8,195 with a category attached, or 80.5%. 3 manufacturers reported payments, led by E.r. Squibb & Sons, L.L.C. at 56.2% of the total. Reporting peaked in 2019 at $8,060 and has fallen 99.0% since, to $80 in 2025.
Across 15 payments — averaging $546.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- E.r. Squibb & Sons, L.L.C.$5K
- Otsuka Pharmaceutical Co., Ltd.$3K
- Johnson & Johnson$135
Across 170 payments — averaging $7242.42 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Eli Lilly$241K
- Bristol Myers Squibb$203K
- Amgen$202K
- Novartis$176K
- E.r. Squibb & Sons, L.L.C.$90K
- UCB SA$90K
- plus $231K from 10 others
What the payments were for
- Consulting fees$6,60081%
- Travel & lodging$1,19815%
- Food & beverage$2623%
- Education$1352%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| E.r. Squibb & Sons, L.L.C. | 10 | $4,605 |
| Otsuka Pharmaceutical Co., Ltd. | 3 | $3,455 |
| Johnson & Johnson | 2 | $135 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- ORENCIA$4,352
How this compares
$8,195 in reported general payments places this provider in the 70th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Cosentyx Sensoready PenSecukinumab | 13 | $91,854 |
| BenlystaBelimumab | 16 | $83,149 |
| Orencia ClickjectAbatacept | 15 | $81,103 |
| Actemra ActpenTocilizumab | 14 | $79,375 |
| Hydroxychloroquine Sulfate | 131 | $5,100 |
| Colchicine | 27 | $2,004 |
| MethotrexateMethotrexate Sodium | 37 | $848 |
| Prednisone | 66 | $391 |
| Cyclobenzaprine Hcl | 11 | $130 |
| Gabapentin | 11 | $74 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 19 | $53 |
| Alendronate Sodium | 14 | $39 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in Syracuse
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Kostas BotsoglouCheektowaga$2.6M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Richard FurieNew Hyde Park$746K
- Barry GruberBabylon$742K
- Olga PetrynaNew York$509K
- Sanjay GodhwaniWading River$472K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.